These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12767082)

  • 1. Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs: a prognostic marker for good clinical outcome in human breast carcinoma.
    Span PN; Sweep CG; Manders P; Beex LV; Leppert D; Lindberg RL
    Cancer; 2003 Jun; 97(11):2710-5. PubMed ID: 12767082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung.
    Takemoto N; Tada M; Hida Y; Asano T; Cheng S; Kuramae T; Hamada J; Miyamoto M; Kondo S; Moriuchi T
    Lung Cancer; 2007 Dec; 58(3):376-83. PubMed ID: 17714826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of membrane-anchored matrix metalloproteinase inhibitor reversion inducing cysteine rich protein with Kazal motifs in murine cell lines.
    Takagi S; Hoshino Y; Osaki T; Okumura M; Fuginaga T
    Exp Oncol; 2007 Mar; 29(1):30-4. PubMed ID: 17431385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer.
    Oshima T; Kunisaki C; Yoshihara K; Yamada R; Yamamoto N; Sato T; Makino H; Yamagishi S; Nagano Y; Fujii S; Shiozawa M; Akaike M; Wada N; Rino Y; Masuda M; Tanaka K; Imada T
    Oncol Rep; 2008 May; 19(5):1285-91. PubMed ID: 18425389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma.
    Asano T; Tada M; Cheng S; Takemoto N; Kuramae T; Abe M; Takahashi O; Miyamoto M; Hamada J; Moriuchi T; Kondo S
    J Surg Res; 2008 May; 146(1):32-42. PubMed ID: 17543340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The membrane-anchored matrix metalloproteinase (MMP) regulator RECK in combination with MMP-9 serves as an informative prognostic indicator for colorectal cancer.
    Takeuchi T; Hisanaga M; Nagao M; Ikeda N; Fujii H; Koyama F; Mukogawa T; Matsumoto H; Kondo S; Takahashi C; Noda M; Nakajima Y
    Clin Cancer Res; 2004 Aug; 10(16):5572-9. PubMed ID: 15328199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
    Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
    J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of reversion-inducing cysteine-rich protein with Kazal motifs expression in resected pathologic stage IIIA N2 non-small-cell lung cancer.
    Takenaka K; Ishikawa S; Yanagihara K; Miyahara R; Hasegawa S; Otake Y; Morioka Y; Takahashi C; Noda M; Ito H; Wada H; Tanaka F
    Ann Surg Oncol; 2005 Oct; 12(10):817-24. PubMed ID: 16132376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer.
    Cho YB; Lee WY; Song SY; Shin HJ; Yun SH; Chun HK
    Hum Pathol; 2007 Nov; 38(11):1603-10. PubMed ID: 17669467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis.
    Masui T; Doi R; Koshiba T; Fujimoto K; Tsuji S; Nakajima S; Koizumi M; Toyoda E; Tulachan S; Ito D; Kami K; Mori T; Wada M; Noda M; Imamura M
    Clin Cancer Res; 2003 May; 9(5):1779-84. PubMed ID: 12738734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer.
    van der Jagt MF; Sweep FC; Waas ET; Hendriks T; Ruers TJ; Merry AH; Wobbes T; Span PN
    Cancer Lett; 2006 Jun; 237(2):289-97. PubMed ID: 16046057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RECK gene expression in hepatocellular carcinoma: correlation with invasion-related clinicopathological factors and its clinical significance. Reverse-inducing--cysteine-rich protein with Kazal motifs.
    Furumoto K; Arii S; Mori A; Furuyama H; Gorrin Rivas MJ; Nakao T; Isobe N; Murata T; Takahashi C; Noda M; Imamura M
    Hepatology; 2001 Jan; 33(1):189-95. PubMed ID: 11124835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing cysteine-rich protein with Kazal motifs) in inflamed synovial membranes of patients with rheumatoid arthritis.
    van Lent PL; Span PN; Sloetjes AW; Radstake TR; van Lieshout AW; Heuvel JJ; Sweep CG; van den Berg WB
    Ann Rheum Dis; 2005 Mar; 64(3):368-74. PubMed ID: 15485996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness.
    Kang HG; Kim HS; Kim KJ; Oh JH; Lee MR; Seol SM; Han I
    J Orthop Res; 2007 May; 25(5):696-702. PubMed ID: 17262820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) as a prognostic indicator in gastric cancer.
    Song SY; Son HJ; Nam E; Rhee JC; Park C
    Eur J Cancer; 2006 Jan; 42(1):101-8. PubMed ID: 16324834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer.
    Takenaka K; Ishikawa S; Kawano Y; Yanagihara K; Miyahara R; Otake Y; Morioka Y; Takahashi C; Noda M; Wada H; Tanaka F
    Eur J Cancer; 2004 Jul; 40(10):1617-23. PubMed ID: 15196549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma.
    Xu J; Wu S; Shi X
    J Orthop Res; 2010 Dec; 28(12):1621-5. PubMed ID: 20973064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of the RECK-tumor and metastasis suppressor gene in glioma invasiveness.
    Correa TC; Brohem CA; Winnischofer SM; da Silva Cardeal LB; Sasahara RM; Taboga SR; Sogayar MC; Maria-Engler SS
    J Cell Biochem; 2006 Sep; 99(1):156-67. PubMed ID: 16791855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.